From the CRTC1-MAML2 regulated gene list (Additional file 2: Table S1), we have selected several genes that were known to be critical players in tumor development and progression, or therapeutic targets with clinical or preclinical inhibitors available, or potential diagnostic or prognosis markers (Table 1). This evidence concerns the gene MAML2 and neoplasm.